United States of America, in No. 82-1605 v. Fmc Corporation, in No. 82-1640

717 F.2d 775, 219 U.S.P.Q. (BNA) 761, 1983 U.S. App. LEXIS 16953
CourtCourt of Appeals for the Third Circuit
DecidedSeptember 13, 1983
Docket82-1605, 82-1640
StatusPublished
Cited by16 cases

This text of 717 F.2d 775 (United States of America, in No. 82-1605 v. Fmc Corporation, in No. 82-1640) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States of America, in No. 82-1605 v. Fmc Corporation, in No. 82-1640, 717 F.2d 775, 219 U.S.P.Q. (BNA) 761, 1983 U.S. App. LEXIS 16953 (3d Cir. 1983).

Opinion

OPINION OF THE COURT

ADAMS, Circuit Judge.

! The question whether Congress has impliedly authorized a right of action to enforce a statute raises important issues unifier the doctrine of the separation of powers. Whether the right of action is asserted by a private party or by the United States government, these issues are of equally broad import. In this case, the United States claims a right of action to sue to invalidate a patent under 35 U.S.C. § 135(c). No provision of law expressly ¶anctions such an action. It is now necessary to decide whether Congress neverthe-ljess impliedly authorized lawsuits by the United States to invalidate a patent when ihe patent holder violates 35 U.S.C. § 135(c) by not filing with the government the agreements executed to settle a patent interference dispute. We hold that it did not.

I.

| FMC Corporation is a manufacturer of agricultural insecticides. In 1968 FMC and á competitor, Bayer A.G., settled a patent interference proceeding 1 in which Bayer had contested the rights to a patent on carbofuran, 2 an agricultural insecticide. 3 FMC and Bayer memorialized their 1968 interference settlement in five documents.

The agreement applicable to the United Sltates settled the interference claim be-ween FMC and Bayer then pending in the United States Patent Office. It also stipulated that FMC would retain the exclusive right to manufacture and sell carbofuran in

*777 this country; that FMC was to sell carbofu-ran to a Bayer subsidiary, Chemagro, at favorable prices; and that FMC was to disclose to Chemagro the technology to produce earbofuran.

In the other four agreements, FMC and Bayer disposed of patent rights in Canada and certain countries of Central and South America. The agreements also established the terms under which earbofuran would be produced and its trademark licensed.

On September 18, 1968, FMC filed with the Patent Office only the settlement agreement applicable in the United States. It was deposited in accordance with 35 U.S.C. § 135(c) (1976), which provides that any “agreement or understanding between parties to an interference” made “in connection with or in contemplation of the termination of the interference” shall be filed in the Patent and Trademark Office before termination of the interference. The sanction for the failure to file an agreement is the permanent unenforceability of both the patent and the agreement. 4 FMC did not, however, file the other four agreements with the Patent Office, apparently believing that none of these four agreements was made “in connection with or in contemplation of” the termination of the United States interference.

All five agreements among FMC, Bayer, and Chemagro came to the attention of the Antitrust Division of the Department of Justice in 1978, during an investigation of possible Sherman Act violations on the part of FMC. The Department of Justice ascertained that FMC had not filed four of the five agreements with the Patent Office and initiated the present action against FMC on April 23, 1980. The complaint alleged that each of the four unfiled agreements was “made in connection with or in contemplation of” the termination of an interference proceeding, and that none of the four agreements was filed with the Patent Office in accordance with 35 U.S.C. § 135(c). The United States sought a declaration that by not filing the four agreements FMC violated section 135(c), a declaration that FMC’s earbofuran patent be denominated “permanently unenforceable,” and an injunction enjoining the patent’s enforcement.

On May 21,1981, the district court denied FMC’s motion to dismiss the government’s suit for failure to state a claim, holding that section 135(c) creates an implied right of action in favor of the United States to declare a patent invalid and to enjoin its enforcement. 5 The district court denied FMC’s motion to permit an interlocutory appeal from this order, and directed that the parties proceed to trial on the question whether the four unfiled agreements were made “in connection with or contemplation of” the termination of the 1968 dispute. After extended litigation, the district court entered judgment on the merits for FMC on August 24, 1982, finding that none of the four unfiled agreements was made “in connection with or contemplation of” the termination of an interference as those words are used in section 135(c).

The United States appeals from the district court order entering judgment on the merits for FMC. FMC cross appeals from the district court’s order holding that section 135(c) creates an implied right of action in favor of the United States. We have jurisdiction under 28 U.S.C. § 1291 (1976).

II.

The statute under which the United States claims a right of action, 35 U.S.C. § 135(c) (1976), originated with President Kennedy’s “Consumer’s Protection and Interest Program.” In a 1962 Message on the *778 State of the Union, the President proposed a variety of reforms intended to fill “serious statutory gaps” in consumer legislation, including “laws promoting competition and prohibiting monopoly.” See Message from the President of the United States Relative to Consumers’ Protection and Interest Program, H.R.Doc. No. 364, 87th Cong., 2d Sess. 6, 9-10, reprinted in 108 Cong.Rec. 4167, 4169-70 (1962) [hereinafter President’s Message ].

Among the measures endorsed by the President was legislation “which would provide subpoena powers for civil as well as criminal antitrust investigations.” Id. at 9, 108 Cong.Rec. at 4170. This statute, eventually enacted as the 1962 Antitrust Civil Process Act, 6 authorizes the Justice Department’s Antitrust Division to issue a “Civil Investigative Demand” (or “CID”) for “any information[ ] relevant to a civil antitrust investigation.” 15 U.S.C. § 1312(a) (Supp. V 1981). The CID is the conventional means by which the Division obtains information prior to the filing of a complaint. See United States v. Consolidated Foods Corp., 455 F.Supp. 142, 146 (E.D.Pa.1978). It apparently was the means by which the Division obtained access to the five agreements between FMC and Bayer in this case. The Civil Process Act imposes stringent confidentiality requirements on the use of information obtained in response to a CID. 7

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
717 F.2d 775, 219 U.S.P.Q. (BNA) 761, 1983 U.S. App. LEXIS 16953, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-of-america-in-no-82-1605-v-fmc-corporation-in-no-82-1640-ca3-1983.